Biliary, fecal and urinary excretion of [3H]-prostaglandins in the rat.
The profiles of biliary, fecal and urinary excretion of tritium labeled prostaglandins (PG's) of differing biological activity were investigated in the rat. The PG's (10 micrograms/kg: 2 to 50 microCi/rat, in 1 ml polyethylene glycol-400) were administered intragastrically. Excretion data were expressed as a percentage of the total administered radioactivity. For the orally administered PG's 11R-methyl-16R-fluoro-15R-hydroxy-9-oxoprosta-ci s-5-trans-13-dienoic acid and its methyl ester, excretion was equally divided between urine and feces. The fecal and urinary profile of excretion of 3H after prostacyclin (PGI2) was similar to that following administration of 11R, 16, 16-trimethyl-15R-hydroxy-9-oxoprosta-cis-5-trans-13-dienoic acid (trimoprostil), a PG with antisecretory-antiulcer potential. However, PGI2 was very poorly absorbed from the intestine, while the absorption of trimoprostil was very efficient. Biliary excretion, with little entero-porto-hepatic biliary circulation, was the main route of elimination of trimoprostil, thereby resulting in rapid elimination of drug-related products and diminishing the potential for systemic liability in the rat.
D000818:Animals; D001646:Bile / Q000378:metabolism*; D015232:Dinoprostone / Q000031:analogs & derivatives*; D011464:Epoprostenol / Q000378:metabolism; D005243:Feces / Q000032:analysis; D008297:Male; D011453:Prostaglandins / Q000378:metabolism* / Q000652:urine; D011459:Prostaglandins E, Synthetic / Q000378:metabolism; D051381:Rats; D011919:Rats, Inbred Strains
D011453:Prostaglandins; D011459:Prostaglandins E, Synthetic; C038879:trimoprostil; D011464:Epoprostenol; D015232:Dinoprostone